Investments, Funding & Disinvestment

This building will accommodate up to 250 researchers and provides a collaborative workspace with modular laboratories designed to support both growth and interdisciplinary exchange.

Construction is expected to be complete by the third quarter of 2027, at which point the site’s workforce is also set to double.

Wegovy HD became the fourth drug to receive FDA approval through the Commissioner’s National Priority Voucher pilot programme.

The companies are competing for a share of India’s Semaglutide market, which analysts estimate will reach USD1 billion over the next two years.

This transaction grants Collegium a second branded ADHD medication to complement its existing Jornay PM offering.

Psoriasis is a chronic autoimmune disorder in which skin cells multiply excessively, creating thick, itchy, scaly patches that affect more than 8 million Americans.

Novartis will direct the funds toward upgrading its manufacturing plant in Beijing and expanding its R&D campus in Shanghai, where it also houses its Chinese headquarters.

The transaction, which remains subject to customary regulatory approvals, marks the beginning of what both firms describe as Syntegon’s next major growth phase.

Construction crews have already broken ground on the expansion project, which Axplora expects to complete by February 2027.

The upgraded complex features modern operating theatres, an intensive care unit (ICU), a high-dependency unit (HDU), and dedicated teaching spaces that enhance both patient care and medical training.